ESMO Congress 2023 Content

ESMO Congress 2023

Mary GreccoESMO Congress 2023 | January 30, 2024

A study aimed to evaluate the feasibility of ddPCR to detect specific driver gene mutations in patients with resected NSCLC.

Katy MarshallPancreatic Cancer | November 3, 2023

Participating patients received PERT at baseline or within 3 months of receiving first-line treatment.

Katy MarshallGEP-NETs | November 3, 2023

Researchers analyzed cabozantinib's ability to improve the progression-free survival rate for patients.

Rob DillardESMO Congress 2023 | October 26, 2023

Perioperative immunotherapy both before and after surgery significantly improves EFS in operable early-stage NSCLC.

Rob DillardESMO Congress 2023 | October 23, 2023

Immune evasion alterations impact the duration of response to checkpoint inhibitors in patients with metastatic NSCLC.

Rob DillardESMO Congress 2023 | October 20, 2023

Neoadjuvant pembrolizumab in combination with chemotherapy followed by resection and adjuvant pembro improves OS in NSCLC.

Rob DillardESMO Congress 2023 | October 20, 2023

Dostarlimab and chemotherapy combo demonstrates robust safety and efficacy in treating metastatic nonsquamous NSCLC.